Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05899738 · ClinicalTrials.gov registry record · Phase 1
A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult Participants
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT05899738 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 32 participants.
The verdict
NCT05899738, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the relative bioavailability for the new iberdomide powder for reconstitution formulation relative to the reference capsule formulation and to assess the effect of food on the pharmacokinetics of powder for reconstitution formulation in healthy adult participants.
Interventions
- DRUG Iberdomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2023-05-18 |
| Est. Completion | 2023-07-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05899738
The ClinicalTrials.gov registry entry for NCT05899738 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Iberdomide is the first listed.
NCT05899738 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05899738 about?
NCT05899738 is a clinical study titled "A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult Participants". The purpose of this study is to evaluate the relative bioavailability for the new iberdomide powder for reconstitution formulation relative to the reference capsule formulation and to assess the effect of food on the pharmacokinetics of powder for reconstitution formulation in healthy adult particip...
What is the current status of trial NCT05899738?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2023-05-18. Estimated completion is 2023-07-06.
What interventions are being tested in trial NCT05899738?
The interventions under investigation include: Iberdomide (DRUG).
Who is sponsoring clinical trial NCT05899738?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.